Prospective Evaluation of the Carbon Footprint and Clinical Utility of IBUS Compared to Colonoscopy and Enterography in UC and CD
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Ulcerative Colitis (UC), Crohns Disease. Basic parameters: 18 years — 80 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- India
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Prospective Evaluation of the Carbon Footprint and Clinical Utility of Intestinal Bowel Ultrasound Compared to Colonoscopy and Enterography in Ulcerative Colitis and Crohn's Disease
Overview
Healthcare contributes approximately 4.4% of global GHG emissions, with diagnostic imaging and endoscopic services being substantial contributors. Colonoscopy and cross-sectional imaging modalities, though indispensable, are associated with high carbon emissions due to electricity use, waste, sterilisation, and transportation. IBUS, a non-invasive, real-time diagnostic modality, is increasingly validated for disease activity assessment in both UC and CD.
Detailed description
Healthcare contributes approximately 4.4% of global GHG emissions, with diagnostic imaging and endoscopic services being substantial contributors. Colonoscopy and cross-sectional imaging modalities, though indispensable, are associated with high carbon emissions due to electricity use, waste, sterilisation, and transportation. IBUS, a non-invasive, real-time diagnostic modality, is increasingly validated for disease activity assessment in both UC and CD. Its low energy footprint and portability make it a potential frontline tool for sustainable IBD follow-up. This study aims to quantify and compare the environmental impact and diagnostic value of IBUS versus conventional imaging strategies in real-world clinical care.
Primary outcome measures
- The electricity consumed, water consumed, waste generated, and Greenhouse Gas (GHG) emissions will be analyzed [Time frame: 12 months]
Eligibility criteria
All consecutive patients undergoing endoscopy procedures with consent for procedures, during the study period will be included
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Case-only
Study locations
India · 2 centers
- AIG Hospitals — Hyderabad
- AIG Hospitals — Hyderabad
Publications
- Expert Panel on Pediatric Imaging; Moore MM, Gee MS, Iyer RS, Chan SS, Ayers TD, Bardo DME, Chandra T, Cooper ML, Dotson JL, Gadepalli SK, Gill AE, Levin TL, Nadel HR, Schooler GR, Shet NS, Squires JH, Trout AT, Wall JJ, Rigsby CK. ACR Appropriateness Criteria(R) Crohn Disease-Child. J Am Coll Radiol. 2022 May;19(5S):S19-S36. doi: 10.1016/j.jacr.2022.02.020. PMID 35550801
- Namburar S, von Renteln D, Damianos J, Bradish L, Barrett J, Aguilera-Fish A, Cushman-Roisin B, Pohl H. Estimating the environmental impact of disposable endoscopic equipment and endoscopes. Gut. 2022 Jul;71(7):1326-1331. doi: 10.1136/gutjnl-2021-324729. Epub 2021 Dec 1. PMID 34853058
- Lenzen M, Malik A, Li M, Fry J, Weisz H, Pichler PP, Chaves LSM, Capon A, Pencheon D. The environmental footprint of health care: a global assessment. Lancet Planet Health. 2020 Jul;4(7):e271-e279. doi: 10.1016/S2542-5196(20)30121-2. PMID 32681898
Identifiers
NCT: NCT07431983 · IBUS1